Drug Price Transparency Act of 2023
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Drug Price Transparency Act of 2023
This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws.
Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 1131: Drug Price Transparency Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-1131/
"S. 1131: Drug Price Transparency Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-1131/.
S. 1131, 118th Cong. (2026), https://openamerica.io/bill/118-S-1131/.
[S. 1131: Drug Price Transparency Act of 2023](https://openamerica.io/bill/118-S-1131/)